Latest Commercialisation News

EMVision has completed the first stage of a Melbourne Mobile Stroke Unit study, operating its portable brain scanner in homes, ambulances and a workplace. The small, non-diagnostic feasibility study produced strong usability results while pointing to a larger clinical validation step planned for next-generation units.

Lithium Universe has secured selection for a proposed four-year Industry PhD project with Macquarie University and CSIRO to develop microwave-assisted recycling of end-of-life solar panels. The collaboration could strengthen the company’s technology pathway, but its grant, agreement and commercial outcomes remain unconfirmed.

Sparc Technologies has reported a 25% reduction in corrosion creep after adding HydroGraph’s Fractal Graphene to its ecosparc protective coating. The result strengthens the commercial case, but a definitive supply agreement remains conditional on longer testing due in November.

FBR has opened a fully underwritten A$2.5 million share purchase plan to fund testing and commercialisation of its Mantis and Hadrian robotics platforms. Eligible shareholders can subscribe at the lower of A$0.115 or a discounted five-day VWAP, with one five-year option attached to each share issued.

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.

Green360 Technologies says more than 3,500 cubic metres of concrete containing its MKX metakaolin product has now been used across major Melbourne infrastructure projects. The milestone gives the company a growing field record while it develops demand before committing to dedicated large-scale production.

ABx Group and its ALCORE subsidiary have received nearly $600,000 in R&D tax offsets, while ALCORE has completed repayment of $2.61 million in unused government grant funds. The company is now awaiting a decision on a separate Industry Growth Program application worth up to $5 million.

Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.

Adisyn says the USPTO has allowed its third US patent application, extending its graphene deposition claims from metallic surfaces to non-metallic semiconductor materials. The allowed claims also include low-temperature processing and in-process quality checks, although commercial adoption remains unconfirmed.

Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.

Pathkey.AI has appointed Nanyang Technological University chip design and AI specialist Professor Anupam Chattopadhyay to the new Advisory Board supporting Chipforge. The appointment adds technical and commercialisation experience as the AI-native semiconductor platform moves from development towards a product launch, although no launch date or commercial contract was disclosed.

H3 Energy says four prospective partners have completed initial evaluations of its Warro gas project and been invited to submit commercial proposals. At Alinya, multiple global energy companies have signed confidentiality agreements and entered the data room, but no binding farm-out deal has yet been secured.